NEW YORK (GenomeWeb) – Contextual Genomics and the Personalized Medicine Initiative today announced that ArcherDx has joined the Canadian National Access Project for Cancer Testing.

ArcherDx's gene fusion assays will be used to help identify lung cancer gene mutations, Contextual Genomics CEO Chris Wagner said in a statement. ArcherDx's FusionPlex technology can detect EML4-ALK gene fusions and will "enhance our cancer panel tests to identify this mutated gene fusion in lung cancer patients," he said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.